Owing to the success of palbociclib, additional orally bio-available CDK4 inhibitors with low nanomolar IC50 values against CDK4/6 have been approved for use in the treatment of HR+/HER2- metastatic breast cancers (MBCs) in combination with other approved therapies. This evidence concerns the gene CDK4 and maternal uniparental disomy of chromosome 20.